Literature DB >> 3456253

Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy.

H Halila, U H Stenman, M Seppälä.   

Abstract

Circulating CA 125 levels were studied in patients with gynecologic cancer and pelvic inflammatory disease, and in pregnant women. The CA 125 level was elevated (greater than 35 U/ml) in 69% (9/13) of patients with active ovarian cancer, in 32% (7/22) of patients with active cervical or endometrial cancer, in 24% (11/46) of pregnant women, and in 33% (10/30) of patients with acute pelvic inflammatory disease. Sixty-three other patients with nonmalignant gynecologic disorders, including 15 patients with ectopic pregnancy, had normal CA 125 levels. The occurrence of elevated CA 125 levels in patients with pelvic inflammatory disease can limit the use of the assay for diagnosis of cancer in young women. Gynecologic tumors may be associated with inflammatory reactions that may contribute to elevated CA 125 levels in some cancer patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3456253     DOI: 10.1002/1097-0142(19860401)57:7<1327::aid-cncr2820570713>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Elevation of carcinoembryonic antigen and CA-125 in a patient with multivisceral tuberculosis.

Authors:  M Mansour; E R Linden; S Colby; G Posner; F Marsh
Journal:  J Natl Med Assoc       Date:  1997-02       Impact factor: 1.798

2.  Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation.

Authors:  H Yucel; H Kaya; A Zorlu; K Yıldırımlı; E Sancakdar; H Gunes; R Kurt; U Ozgul; O O Turgut; M B Yilmaz
Journal:  Herz       Date:  2014-09-27       Impact factor: 1.443

3.  Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies.

Authors:  A M Paoletti; G G Serra; V Mais; S Ajossa; S Guerriero; M Orrù; G B Melis
Journal:  J Assist Reprod Genet       Date:  1995-04       Impact factor: 3.412

4.  Elevated CA125 serum levels in a patient with tuberculous peritonitis.

Authors:  A Imai; T Itoh; K Niwa; T Tamaya
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

5.  Pelvic mass associated with raised CA 125 for benign condition: a case report.

Authors:  Viren Asher; Robert Hammond; Tim J Duncan
Journal:  World J Surg Oncol       Date:  2010-04-16       Impact factor: 2.754

6.  CA 125 secretion by peritoneal mesothelial cells.

Authors:  A M Zeillemaker; H A Verbrugh; A A Hoynck van Papendrecht; P Leguit
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

7.  The prognostic value of post chemotherapy serum CA 125 in epithelial ovarian cancer.

Authors:  M Teeling; P McGing; D N Carney
Journal:  Ir J Med Sci       Date:  1989-03       Impact factor: 1.568

Review 8.  Increased CA 125 in a patient with tuberculous peritonitis: case report and review of published works.

Authors:  D K O'Riordan; A Deery; A Dorman; O E Epstein
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

9.  Relationship between serum CA 125 levels, endometrial thickness and corpus luteum function in different stages of ovarian activity.

Authors:  G Ozakşit; N O Turhan; H Oral; N Doğu; O Gökmen
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

Review 10.  Therapeutic management of epithelial ovarian cancer during pregnancy.

Authors:  L Minig; L Otaño; I Diaz-Padilla; R Alvarez Gallego; M G Patrono; J Valero de Bernabé
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.